From lab to clinic
Disrupted biological signaling pathways can lead to cancer. Proteomedix develops highly selective and targeted biomarkers by analyzing and understanding the specific signaling pathways. While the latest mass spectrometry-based proteomics technology was used during the research phase to identify the protein biomarkers, our final tests are immunoassay-based. This offers a rapid, sensitive, reproducible, cost effective and easily manageable analysis. The reagents used are stable and the method is established in routine diagnostic laboratories to guarantee wide application of our first test, Proclarix.
